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ABSTRACT 
 
A major obstacle to curing chronic myeloid leukaemia (CML) is residual disease 
maintained by tyrosine kinase inhibitor (TKI)-persistent leukemic stem cells (LSCs). 
These are BCR-ABL1 kinase-independent (1, 2), refractory to apoptosis (3, 4) and 
serve as a reservoir to drive relapse or TKI-resistance. We demonstrate that 
Polycomb Repressive Complex 2 (PRC2) is mis-regulated in chronic phase (CP) 
CML LSCs. This is associated with extensive reprogramming of H3K27me3 targets 
in LSCs, thus sensitizing them to apoptosis upon treatment with an EZH2-specific 
inhibitor (EZH2i). EZH2i does not impair normal hematopoietic stem cell (HSC) 
survival. Strikingly, treatment of primary CML cells with either EZH2i or TKI alone 
caused significant up-regulation of H3K27me3 targets, and combined treatment 
further potentiated these effects and resulted in significant loss of LSCs compared to 
TKI alone, in vitro, and in long-term bone marrow murine xenografts. Our findings 
point to a promising epigenetic-based therapeutic strategy to more effectively target 
LSCs in CML patients receiving TKIs. 
 
SIGNIFICANCE 
 
In CML, TKI-persistent LSCs remain an obstacle to cure and approaches to 
eradicate them remain a significant unmet clinical need. We demonstrate that EZH2 
and H3K27me3 reprogramming is important for LSC survival, but renders them 
sensitive to the combined effects of EZH2i and TKI. This represents a novel 
approach to more effectively target LSCs in patients receiving TKI treatment. 
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INTRODUCTION 
 
Chronic myeloid leukemia (CML) is a clonal HSC disorder, arising through the 
acquisition and expression of the fusion BCR-ABL1 tyrosine kinase which stimulates 
a number of key survival pathways to drive the disease. Despite the introduction of 
TKIs which have transformed the clinical course of CML from a fatal to a 
manageable disease for the vast majority of patients, only ~10% of those who 
present in chronic phase can discontinue treatment and maintain a therapy-free 
remission without relapse (5). The remaining 90% of patients require life-long TKIs 
and can experience serious side effects, compliance issues and high costs, or they 
develop TKI-resistance (20-30% of cases), and/or progress to advanced disease for 
which there are no effective drug therapies. The low cure rate in CML is thought to 
be due to a pool of TKI-persistent and BCR-ABL1 kinase-independent (1) LSCs. 
LSCs in CML are defined as Philadelphia chromosome-positive (Ph+) CD34+CD38- 
primitive progenitor cells that show a higher capacity to engraft in 
immunocompromised mice than bulk CD34+ cells (6), have stem cell properties 
(quiescence and self-renewal), are prone to genomic instability (7) and resistant to 
apoptosis (3, 4). Novel therapeutic strategies that target these LSCs must be 
developed to address an important unmet clinical need for the vast majority of 
patients currently on TKI therapy. 
 
The epigenetic “writer” complex PRC2 is fundamental for defining stem cell identity 
where it primarily regulates gene repression using H3K27me3 (8). Whilst its 
methyltransferase activity can be mediated by either EZH1 or EZH2; aberrant 
H3K27me3 and EZH2 activity has been implicated in the progression or poor 
prognosis of solid tumors and hematological malignancies (9, 10). However, little is 
known about the role of EZH2 in CML and unlike other myeloid malignancies, 
inactivating mutations of EZH2 in CML are rare, (11, 12) although up-regulation of 
EZH2 can result in a form of myeloproliferative disease (13). 
 
RESULTS 
 
In comparative mRNA profiling of normal and CP CML primary samples 
representative of those in our CML biobank (on average ≥ 95% Ph+ in CD34+ or 
P a g e  | 4 
 
CD34+CD38- cells; see Methods), we observed significant mis-regulation in the 
levels of several PRC2 components - predominantly between CD34+CD38- HSCs 
and CD34+CD38- LSCs, and to a lesser extent between CD34+CD38+ leukemic and 
normal CD34+CD38+ progenitors (LPCs and HPCs respectively) (Fig. 1a; 
Supplementary Fig. S1a-c). Significant down-regulation of EZH1 in LSCs was 
found often in combination with EZH2 up-regulation, creating a scenario where the 
relative levels of EZH2 compared to EZH1 increased 2-16 fold across the ten CML 
samples we examined (Fig. 1a). Levels of EZH2, as well as other PRC2 
components, were significantly down-regulated in LSCs treated with TKI in vitro, 
indicative of kinase dependent regulation. The levels of EZH1, however, appeared 
kinase independent, thus maintaining an EZH balance favouring EZH2 in TKI-
persistent cells (Supplementary Fig. S2a-c).  
 
To understand the molecular consequences of PRC2 mis-regulation, we performed 
ChIP-sequencing in normal and CML primary stem and progenitor cell samples (a 
first in CML LSCs). We identified statistically significant changes in H3K27me3 levels 
at promoters in three pairwise comparisons (Fig. 1b; Supplementary Fig. S3a). In 
total, across the three CML samples, changes in H3K27me3 levels were identified at 
4101 promoters, 83% of which were unique to CML (Fig. 1c). A quarter of these 
were common to all three samples and consistent with gains or losses of EZH2 
target genes (Supplementary Fig. S3b). A significant majority of these changes 
(2978; 73%) occurred between the HSC and LSC, indicative of extensive epigenetic 
reprogramming in the LSC. 
  
Whilst the repressive function of EZH2 and H3K27me3 is well documented, changes 
in gene expression at EZH2 target genes are not always mechanistically linked to 
H3K27me3 levels in normal hematopoiesis (14). We therefore asked what impact 
H3K27me3 reprogramming would have on gene expression in CML. Significant 
mRNA expression changes between normal and leukemic stem and progenitor cells 
were determined globally (Supplementary Fig. S4a; Supplementary Table S1) and 
from these we identified a subset of H3K27me3 reprogrammed target genes, whose 
mRNAs were either up- or down-regulated (examples shown, Fig. 1d). In agreement 
with previous observations (14), we found no evidence that H3K27me3 levels were 
linked to changes in gene expression during normal cell fate decisions (HSC → 
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HPC) (Fig. 1e). However, in the three CML samples, the association between 
changes in gene expression and H3K27me3 levels was significantly different from 
that predicted by H3K27me3 reprogramming (Fig. 1e; Supplementary Fig. S4b) 
and indicative of H3K27me3 having its canonical repressive role. This association 
was most significant in the “early” changes (HSC vs LSC), particularly amongst 
promoters reprogrammed in all 3 CML samples (common; Fig. 1f; Supplementary 
Fig. S4c), and pointed to an altered dependency between H3K27me3 and gene 
expression primarily in the LSC (Fig. 1g).  
 
Based on the epigenetic evidence, we hypothesized that EZH2 inhibition would 
represent a potential novel therapeutic strategy to selectively target LSCs given that 
HSCs require EZH1 (14) for survival but not EZH2 (15). We therefore treated CML 
and normal primary cells in vitro with a highly specific EZH2i, GSK343 (16) (Fig. 2a; 
Supplementary Fig. S5a-h). We confirmed a selective dose-dependent decrease, 
but not complete loss, of H3K27me3 in response to EZH2i in both CML and normal 
CD34+ cells (Fig. 2b, Supplementary Fig. S5b). Treatment of bulk CML CD34+ cells 
and LSCs with the EZH2i resulted in modest but significant (≈ 20-40%) reductions in 
viable cells including quiescent (undivided; CTVmax staining; see Methods) cells (17), 
along with increases in apoptosis, particularly in undivided cells (Fig. 2c,d; 
Supplementary Figs. S5a,c, S6a-c). More pronounced decreases (≈ 60-80%) 
however were seen for total colony forming cell (CFC) and primitive 
granulocyte/erythroid/macrophage/megakaryocyte (GEMMs) outputs (Fig. 2e; 
Supplementary Figs. S5a,d, S6a,b,d), and for those of long-term-culture initiating 
cell (LTC-IC) assays which enrich for primitive LSCs (Fig. 2f; Supplementary Fig. 
S5e). This suggested that the primitive stem and progenitor cells were being 
preferentially targeted by EZH2i, supporting our hypothesis. Similar results were 
seen for CML CD34+ cells treated with other novel EZH2i (Supplementary Fig. 
S5a). Normal CD34+ cells treated with EZH2i were spared from the deleterious 
effects seen in CML cells (Fig. 2c-f; Supplementary Fig. S5f-h), thus 
demonstrating a potential therapeutic window for EZH2is in CML. We observed 
similar results using shRNAs against EZH2 in a CML cell line (Supplementary Fig. 
S7a-c) and in CML CD34+ cells (Fig. 2g). On-target effects were confirmed by global 
mRNA analysis, where CML and normal CD34+ cells treated with EZH2i both 
showed significant over-representation of up-regulated H3K27me3 targets (Fig. 2h; 
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Supplementary Fig. S8a,b; Supplementary Table S2). However, relatively few 
EZH2i-deregulated targets were in common between CML and normal and only CML 
cells showed significant up-regulation of apoptotic pathways (Fig. 2i; 
Supplementary Table S3). This provides further mechanistic support that global 
epigenetic reprogramming results in an altered dependency on EZH2 and 
H3K27me3 in CML cells, and this sensitizes LSCs, but not HSCs, to EZH2 inhibition. 
 
An important area of unmet clinical need in CML is the eradication of a sup-
population of LSCs that are refractory to TKI treatment (18, 19). By analysing global 
datasets of CML CD34+ cells or LSCs treated with EZH2i or TKI and by using an 
additive model for combined drug effects, we predicted that a combination of EZH2i 
and TKI would be more effective at up-regulating H3K27me3 target genes than 
EZH2i alone (Supplementary Figs. S9a-d, S10a-d). This was, in part, attributable to 
TKI treatment alone resulting in substantial up-regulation of H3K27me3 targets (Fig. 
3a). However, we found little evidence that TKI or EZH2i returned mRNA levels of 
H3K27me3 targets to those found in normal stem or progenitor cells 
(Supplementary Figs. S11a-c, S12). 
 
To provide support for our in silico prediction, we treated CML and normal CD34+ 
cells and LSCs with EZH2i and dasatinib (DAS), alone and in combination (Fig. 3b-f; 
Supplementary Fig. S5c-e, S6b-d). EZH2i selectively targeted the loss of 
H3K27me3 in the presence of DAS (Fig. 3b; Supplementary Fig. S5b). 
Furthermore, combination treatment with DAS and EZH2i led to a significant 
reduction in cell viability, even in the undivided ‘TKI-persistent’ cells (Fig. 3c), and 
was accompanied by increased apoptosis (Fig. 3d) and a pronounced reduction in 
CFC and CFC/GEMM outputs compared to DAS treatment alone (Fig. 3e). 
Furthermore, combined EZH2i and DAS treatments reduced LTC-IC outputs to 1% 
of those of no drug controls (Supplementary Fig. S5e) and the effects of EZH2i in 
the presence of DAS were more than additive (Fig. 3f). DAS treatment similarly 
reduced cell viability and the CFC potential of cells in which EZH2 was knocked 
down by shRNAs (Fig. 3g).  
 
To determine the effect treatment would have on LSCs within a bone marrow 
microenvironment, human CD34+ cells were engrafted into NOD scid gamma (NSG) 
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mice for 10-13 weeks and then treated in vivo with nilotinib (NIL) and an EZH2i 
(EPZ-6438) (20) singly and in combination for either 14 or 25 days (Fig. 3h). After 14 
days of treatment, we observed significant reductions in levels of leukemic (Ph+) 
human CD45+ cells, CD45+CD34+ progenitor cells, and primitive CD45+CD34+CD38- 
stem cells in the bone marrow of mice treated with both NIL and EZH2i compared to 
NIL treatment alone (Supplementary Fig. S13a-d). Importantly, after 25 days of 
treatment, we observed near complete elimination of CD45+CD34+ progenitor cells 
(Fig. 3i,j; Supplementary Fig. S13e,f) and greater than a 70% reduction of 
CD45+CD34+CD38- cells (Fig. 3k) in combined NIL/EZH2i treatment compared to 
NIL alone. Again, the effects of EZH2i on CML stem and progenitor cells in the 
presence of NIL appeared more than additive in vivo, and mirrored our in vitro 
findings. These results taken together demonstrate a clear rationale for combining 
TKI treatment with EZH2i, given the efficacy of an EZH2i at targeting primitive CML 
cells not eradicated by TKI alone.  
 
As TKI-persistent cells are refractory to apoptosis (3, 4), we examined the 
mechanism of action of combined DAS plus EZH2i on the mRNA expression of a set 
of genes, including 14 H3K27me3 targets from apoptotic pathways (Fig. 4a). BCL6, 
an H3K27me3 target and a known repressor of p53 and CDKN2A (p16/ARF) in TKI-
persistent cells (21, 22) was up-regulated by combined DAS plus EZH2i treatment. 
Nonetheless, there was a significant up-regulation of apoptotic genes, including p53 
transcriptional targets (e.g. CDKN1A, BAX, PUMA, NOXA, TNFRS10B), and an 
enhanced activation of H3K27me3 targets, including CDKN2A, compared to DAS or 
EZH2i treatments alone. In keeping with our phenotypic data, the enhanced 
activation of H3K27me3 targets and apoptotic genes exceeded predicted levels 
based on additive effects (Fig. 4b). Furthermore, we confirmed increased levels of 
the p53 protein in CML CD34+ cells treated with EZH2i and in combination with DAS 
(Fig. 4c). We generated a connectivity map between targets of EZH2 (H3K27me3), 
BCL6 and p53 in the apoptosis pathway (Fig. 4d) and propose that EZH2 inhibition, 
when potentiated by TKI, could engage apoptosis downstream of p53 through re-
activation of pro-apoptotic targets (e.g. PUMA, BIM), and/or by directly rescuing p53-
mediated apoptosis by overcoming BCL6- and EZH2- mediated repression upstream 
of p53. 
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DISCUSSION 
 
Due to increased patient survival, CML will become the most prevalent form of 
leukemia in the next 20-30 years (23), with TKI-persistent LSCs remaining a 
significant unmet clinical need for the majority of these patients. Since TKIs are 
highly effective against the bulk of leukemic cells and are generally well tolerated by 
most chronic phase CML patients, new therapies that target LSCs must be effective 
and safe when combined with TKI. Our pre-clinical results, derived from more than 
40 primary samples, and hypothesis-driven by global analyses, demonstrate that 
inhibition of EZH2 in combination with TKI is comparable, if not more effective, than 
other novel strategies for targeting CML LSCs (Supplementary Table S4); none of 
which have reached the clinic to supplement or replace TKI as the standard of care. 
Given that EZH2 can have tumor suppressor or oncogenic roles, further 
investigations however are required to optimise pre-clinical therapeutic strategies, 
and to identify biomarkers of EZH2 and H3K27me3 inhibition in CML cells. 
Nonetheless, novel, orally-administered EZH2 inhibitors currently in trials are 
showing low toxicity, significant reductions of H3K27me3 levels at clinically 
achievable doses, and promising objective responses across a range of tumour 
types. These early trial data, taken together with our results and those of Xie et al. 
(24), point to a promising new avenue for the development of the first epigenetic 
therapy for the treatment of CML. 
 
METHODS 
 
Primary samples. Primary CML samples (Ph+ in > 90% of CD34+ cells) were 
obtained from patients with CP CML obtained at point of diagnosis prior to TKI 
treatment (n = 32 bioreplicates in total, for experiments described in this paper). 
Normal (i.e., non-CML) control primary samples were obtained by granulocyte-
colony stimulating factor (G-CSF) mobilisation from individuals negative for bone 
marrow involvement upon lymphoma staging or from normal cadaveric bone marrow 
(BM) samples (normal controls; n = 12 bioreplicates). In all instances, ethical 
permission was with written informed consent (West of Scotland Research Ethics 
Service; REC Ref 10/S0704/2 and REC Ref 15/WS/0077). See also Supplementary 
Table S5. Primary CML samples were randomly chosen for the experiments 
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described below and in the text without prior knowledge of clinical outcome or 
response to TKI. The investigators were not blinded to the experimental conditions 
when assessing the outcomes and no datasets were excluded from analysis (for all 
in vitro assays). Experiments on live vertebrates (NSG mice) were performed as 
described below. 
 
Primary samples were stored frozen as mononuclear cells (MNCs) isolated by 
density gradient centrifugation or as CD34+ cells isolated using CliniMACS (Miltenyi 
Biotech). After thawing, CML cells were recovered by culturing in physiological 
growth factors (SCF 0.2ng/ml, G-CSF 1ng/ml, GM-CSF 0.2ng/ml, IL-6 1ng/ml, LIF 
0.05ng/ml, MIP-α 0.2ng/ml, StemCell Technologies), while normal control stem cells 
were cultured in 5 growth factors (SCF 100 ng/ml, G-CSF 20 ng.ml, IL-3 20 ng/ml, 
IL-6 20 ng/ml, Flt3 100 ng/ml). For isolation of HSC/LSC (CD34+CD38-) and 
HPC/LPC (CD34+CD38+), MNCs or CD34+ cells were stained with CD34-APC, 
CD38-FITC or CD38-PerCP-Cy™5.5 antibodies (555824, 555259, 551400 
respectively; BD Biosciences), before being subject to fluorescence activated cell 
sorting (FACS) to obtain the appropriate populations using a FACS Aria cell sorter 
(Beckton Dickinson). 
 
Cell culturing. For experiments involving GSK343, CML and normal primary cells 
were cultured as above for the treatment regimens described below and in the text 
with media change every 3 days. For experiments involving treatment of LSCs with 
TKIs (imatinib (IM)/5µM, dasatinib (DAS)/150 nM and nilotinib (NIL)/5 µM; Bristol-
Myers Squibb and Selleckchem) for up to 7 days, cells were grown in serum-free 
media without growth factors. The KCL22 cell line (CML, blast crisis; obtained from 
DSMZ cell bank in 2014; mycoplasma-negative; authenticated by DSMZ using RT-
PCR for BCR-ABL1 expression and microsatellite repeat typing) was grown in RPMI 
1640 (Sigma) supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 1% 
penicillin-streptomycin. Experiments involving KCL22 cells were performed within 6 
months from the date cells were obtained from DSMZ. 
 
Proliferation, differentiation, apoptosis and colony-forming cell assays for 
EZH2 inhibition with GSK343, GSK126 and EZP-6438. Primary cells from CML 
patients and normal controls (n = 3 each) (CD34+, CD34+CD38-, or CD34+CD38+) 
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were cultured as above for 6 days with or without EZH2 inhibitors and/or DAS (50-
150 nM), with media and drug change every three days. Viable cell numbers (trypan 
blue exclusion) in culture were measured every three days and fold change 
determined relative to input. To monitor proliferation/cell division, cells were labelled 
with cell trace violet (CTV; Invitrogen). Following culture, the cells were co-stained 
with CD34-APC to assess differentiation status and loss of CD34+. CTV and CD34 
levels were analyzed by flow cytometry and the percentage recovery of input for 
CD34+ cells in each cell division was determined. Colcemid treatment was used to 
determine gating for undivided cells. To assess levels of apoptosis, cells were 
incubated with Annexin V-FITC and 7-AAD (556419 and 559925 respectively; BD 
Biosciences) and analysed by flow cytometry. Apoptotic cells were defined as 
Annexin V and Annexin V-7AAD positive. For colony forming cells (CFC) assays, 
cells cultured with or without GSK343 +/- DAS for 6 days were plated in 
methylcellulose (MethoCult™; StemCell Technologies) and the number and 
morphology of colonies determined after 12 days.  Statistical analysis of differences 
in proliferation, CFC counts and apoptosis was performed using one sample t-tests. 
 
LTC-IC assays for EZH2 inhibition with GSK343. Primary CD34+ cells from CML 
patients and normal controls (n = 4 bioreplicates for CML; n = 3 bioreplicates for 
normal) were cultured as above for 3 or 6 days with or without GSK343 (1000 nM) 
and DAS (150 nM). M2-10B4 and SL/SL fibroblasts were established as feeder 
layers and then irradiated at 80 Gy. 5 x 104 cells were then placed in long-term 
culture-initiating culture (LTC-IC) on irradiated feeders in MyeloCultTM (StemCell 
Technologies) and maintained for 5 weeks in duplicate in the absence of drugs. Cells 
were then transferred to CFC assays in duplicate and maintained in culture for 12 
days and then scored as above.  
 
Immunodeficient murine xenograft experiments. CML CD34+ cells were 
transplanted (1×106 cells per mouse) via tail vein injection into female 8-12-week-old 
sub-lethally irradiated (2.25Gy) NOD scid gamma (NSG) mice (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ; The Jackson Laboratory). Human cell engraftment was monitored at 8 
to 12 weeks post-transplantation by FACS for the presence of human CD45+ cells in 
the blood. Mice which showed evidence of human cell engraftment were randomized 
and treated with vehicle/NDC (10% NMP in PEG300), a clinical grade EZH2i (EPZ-
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6438; Medkoo Biosciences), nilotinib (LC Laboratories), or a combination of EPZ-
6438 and nilotinib for 14 or 25 days, commencing at 10-13 weeks post-
transplantation. Drugs or vehicle were administered once daily by oral gavage at a 
dose of 300 mg/kg for EPZ-6438 and 50 mg/kg for nilotinib. Mice were euthanized at 
the end of treatments and marrow contents of ilia, femurs, and tibia were obtained. 
The presence of human CD45, CD34 and CD38 on engrafted cells was assessed by 
FACS. Engraftment data was obtained from n = 3 (14 day treatment) or n = 2 (25 
day treatment) CML CD34+ samples derived from different patients. The 
investigators were blinded to the experimental conditions when assessing the 
outcomes and no datasets or animals were excluded from analysis. Mice were 
handled humanely in accordance with regulations under Home Office License PPL. 
60/4492. 
 
Fluorescence in situ hybridization (FISH). Colonies from LTC-IC colonogenic 
outputs and human CD45+ or CD45+CD34+ cells from NSG xenografts were scored 
for the presence of the Philadelphia chromosome (Ph+). FISH was performed with 
the LS1 BCR-ABL Dual Color, Dual Fusion translocation probe according to the 
manufacturer’s instructions (Abbott Diagnostics). For each LTC-IC, nuclei from at 
least 10 colonies were scored where possible. Two hundred nuclei were scored from 
bone marrow from each xenograft. 
 
EZH2 knockdown.  EZH2 shRNAs were subcloned from the pLKO.1 puro vector 
(Sigma Mission shRNA collection) into the NdeI and SpeI sites of the pLKO.1 GFP 
vector. Sequences for EZH2 shRNA 1 and 3 are 
CCGGGCTAGGTTAATTGGGACCAAACTCGAGTTTGGTCCCAATTAACCT 
AGCTTTTTG and CCGGGCTAGGTTAATTGGGACCAAACTCGAGTTTGGT 
CCCAATTAACCTAGCTTTTTG respectively. A scrambled, non-targeting shRNA 
was used as a control. 10 μg of each shRNA were transfected into 293 T human 
embryonic kidney (HEK) cells along with 6.5 μg Hiv1 and 3 μg VSV-G constructs. 
After 24 hrs, the medium was replaced with DMEM containing 20% serum. KCL22 
cells or CML CD34+ cells were transduced in 2 consecutive rounds of 24 and 48 hrs 
with lentiviral supernatant supplemented with Transdux (Systems Biosciences). 
Transduction efficiency (% GFP+ cells) was measured by flow cytometry. GFP 
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positive cells were isolated by FACS using a FACS Aria cell sorter and knockdown 
assessed at the mRNA and protein level.  
 
Western blotting. Total cellular protein was extracted from primary CML and normal 
samples by direct lysis in laemmli buffer or by acid extraction. Cell lysates were then 
run out on 4-12% SDS-PAGE gels, transferred to PVDF membrane and probed with 
the appropriate antibodies. Antibodies used were for H3K27me3 and H3K27me1 
(see ChIP-sequencing below), histone H3 (9715; New England Biolabs), EZH2 
(5246; New England Biolabs) and p53 (sc-126; Santa Cruz Biotechnology). 
Validation of specificities of, and citations for, these antibodies can be found on the 
manufacturers’ websites. 
 
Experimental analysis by Affymetrix GeneChips, Taqman Low Density Array 
(TLDA) cards and Fluidigm. mRNA was extracted using the RNeasy Mini Kit 
(Qiagen) and DNase I treated on columns using the ribonuclease (RNase)-Free 
DNase Set (Qiagen). Purity was determined by the Agilent Bioanalyzer and Agilent 
RNA 6000 Nano kit (Agilent Technologies). Affymetrix GeneChIP analysis (using 
HuGene-1_0-st-v1 arrays) was performed using 50 ng of total RNA as starting 
material according to manufacturer’s instructions. For q-PCR, cDNA was obtained 
using the High Capacity RNA-to-cDNA kit (Applied Biosystems) or alternatively, 300 
cells were sorted and processed with “Cells direct one-step q RT-PCR” (Invitrogen). 
Real Time qPCR was carried out using FAM-MGB probes for the genes of interest 
on the TLDA (ABI7900, Applied Biosystems) and Fluidigm 48.48 Dynamic Array IFC 
platforms (Fluidigm Corporation, San Francisco, CA, USA). Validation of mRNA 
expression changes determined by Affymetrix GeneChip analysis is shown in 
Supplementary Fig. S14a-e. All oligonucleotide primer pairs available upon request. 
 
Computational analysis of Affymetrix GeneChips. Affymetrix datasets were 
processed using one of two different approaches. For CD34+CD38- and 
CD34+CD38+ normal and CML  datasets generated for this study (E-MTAB-2581, 
Affymetrix HuGe 1.0 ST) or for datasets generated from treatment of CML or normal 
CD34+ with GSK343 (E-MTAB-2893, E-MTAB-3552, Affymetrix HuGe 1.0 ST), 
Bioconductor was used for data preprocessing (affy and aroma.affymetrix 
packages), quality control (simpleaffy package), differential gene expression analysis 
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(limma package) and gene annotation (annotate package). Datasets for CML CD34+ 
cells treated with IM in vivo (GSE12211, Affymetrix Human Genome U133A 2.0) 
were normalised using RMA (affy v1.42.3). Datasets from LSCs treated with DAS, IM 
and NIL (E-MTAB-2594, Affymetrix HuGe 1.0 ST) generated for this study were 
normalised using RMA (oligo v1.28.2) and subsequently merged and batch corrected 
using COMBAT (inSilicoDb v2.0.1, inSilicoMerging v1.8.6). For pathway analysis, 
differentially expressed genes from E-MTAB-2893 and E-MTAB-3552 were analysed 
for enrichment of Panther Pathways using the DAVID Bioinformatics Database. See 
also Supplementary Table S3. 
 
ChIP-sequencing. H3K4me3 (Abcam, ab8580), H3K27me3 (Millipore, 07-449)  and 
H3K27me1 (Millipore, 07-448) ChIPs were performed (validated for specificity as 
previously described (25)) using between 104-106 primary HSCs (CD34+CD38-), 
LSCs (CD34+CD38-) or LPCs (CD34+CD38+) as starting material with no pre-clearing 
of chromatin (n=3 for all cell types). The three CML samples used for ChIP-
sequencing displayed typical patterns of PRC2 mis-regulation (Supplementary Fig. 
S15a-c). ChIP-sequencing libraries (see Supplementary Table S6) were prepared 
according to manufacturer’s protocols (Illumina). HSC, LSC and LPC ChIP-
sequencing was performed in singlicate per bioreplicate and the read data obtained 
was deposited into the European Nucleotide Archive (Access. No. PRJEB8291).  
 
Reads obtained from ChIP-sequencing were aligned to the human genome (hg18; 
NCBI build 36.1) and uniquely mapped reads were extended to 150 bp and 
processed as BED or bigWig files for further analysis and visualisation in the UCSC 
genome browser. H3K27me3 read densities (per 106 reads) at each of 33,626 gene 
promoters were determined for each CML and normal sample across 2 kilobases 
(kb) windows flanking the transcriptional start site (TSS) (1 kb up- and down- stream 
of the TSS). These read densities were quantile normalised to reduce bias and only 
promoters where all three samples gave read densities greater than 0 at a given 
promoter were used for further data mining. As a result, read densities for 26,760 
promoters (H3K27me3) or 24,292 promoters (H3K27me1) were used for the 
analyses described in the text.  
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Bona fide H3K27me3 target genes were defined as follows. k-means clustering of 
ChIP-sequencing read densities/106 reads at a resolution of 50 bp across 5 kb at 
each each of 33,626 promoters (2.5 kb bp up- and down- stream of the TSS) was 
performed by seqMINER (26). Clusters were generated that defined promoters 
having (i) H3K4me3 only, (ii) both H3K4me3 and H3K27me3, or (iii) neither histone 
modification (Supplementary Fig. S16a,b). Membership of gene promoters in these 
three classifications was validated by ChIP qPCR (Supplementary Fig. S17a-c) 
using SYBR-Green Master (Rox) (Roche) in a Stratagene Mx3000P qPCR system 
(Agilent Technologies). Oligonucleotide primer pairs available upon request.  
 
Promoters defined as “H3K4me3 only” or having “neither” histone modification were 
then used as a measure of background noise for H3K27me3 in ChIP-sequencing 
datasets derived from each patient or normal sample. On a per sample basis, those 
promoters with H3K27me3 read densities (across 2 kb promoter windows) that were 
3 standard deviations above background noise were considered as H3K27me3 
targets. In this way, each H3K27me3 ChIP-sequencing dataset had a uniquely 
defined measure of background (i.e., a threshold) above which bona fide H3K27me3 
targets could be identified.  
 
Statistically significant changes in H3K27me3 read densities at promoters of 
H3K27me3 target genes (defined as above) were determined using either Student t-
tests or one-sample t-tests as appropriate. Significance was determined at the level 
of individual promoters. In addition, promoters shown to be statistically significant 
were also required to have at least 1.5 fold changes in H3K27me3 levels to be 
considered as promoters with obvious changes. Promoters ranked as having 
H3K27me1 levels in the top 25% of all promoters genome-wide were used for the 
analysis described in Supplementary Fig. S8a,b. Yates Chi-square or Fischer Exact 
tests were used to determine statistically significant differences between observed vs 
expected frequencies of changes in H3K27me3 at promoters (gains or losses) with 
respect to changes in mRNA expression. Expected frequencies were the number of 
promoters showing gains or losses in H3K27me3 due to global H3K27me3 
reprogramming on a per sample basis, or for common H3K27me3 reprogrammed 
genes. Observed frequencies were the data shown in Supplementary Figure 
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S4b,c. Heatmaps of common H3K27me3 reprogrammed genes (Supplementary 
Fig. S3b) were generated using Cluster 3.0 (27).  
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FIGURE LEGENDS 
 
Figure 1. Mis-regulation of PRC2 leads to H3K27me3 reprogramming and 
increased coupling of H3K27me3 and mRNA expression in CML LSCs. a. Top; 
the mean fold changes in mRNA expression for 6 PRC2 components and BCR-ABL1 
in normal (HSCs and HPCs) and in CML (LSCs and LPCs) cells as determined by 
Fluidigm analysis performed in triplicate. Fold changes (log2) are expressed relative 
to levels found in HSCs. Error bars are standard error measurements (SEMs). 
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Bottom; the mean levels of EZH2 mRNA relative to EZH1 mRNA in each of the 
bioreplicate samples as above. Significant p values (*; Student’s t-test) between 
equivalent cell type comparisons (HSC vs LSC, HPC vs LPC) are shown. 
Bioreplicates are n = 4 (HPC), n = 3 (HSC), n = 10 (LSC), n = 10 (LPC). b. 
Schematic diagram depicts how changes in H3K27me3 levels between normal and 
CML cells were determined with respect to three pairwise cell type comparisons: 
HSCs vs HPCs (“norm”), HSCs vs LSCs (“early”), LSCs vs LPCs (“late”). c. Venn 
diagram depicts the relationship between the numbers of promoters which show 
altered levels of H3K27me3 in three pairwise comparisons (HSC→HPC; HSC→LSC; 
LSC→LPC). d. Examples of H3K27me3 read densities across genes that are up- 
(red arrow) or down-(green arrow) regulated (mRNA) in CML cells compared to 
HSCs. Location of transcription start site and direction of transcription are shown by 
→. Profiles were visualised in the UCSC genome browser (hg18; NCBI build 36.1). 
e. Bar diagrams show the percentages (%) of all reprogrammed promoters having 
significant gains (red) or losses (green) of H3K27me3 (p < 0.05; one sample t-tests) 
when their cognate mRNA levels are down- (↓) or up- (↑) regulated (Affymetrix 
analysis) in each of three pairwise comparisons for n = 3 bioreplicate CML(1,2,3) and 
normal samples. f. Bar diagrams show the percentages (%) of all promoters 
reprogrammed in all three CML samples (common) having significant gains (red) or 
losses (green) of H3K27me3 (p < 0.05; one sample t-tests) when their cognate 
mRNA levels are down- (↓) or up- (↑) regulated (Affymetrix analysis) as above. In e 
and f, expected percentages of H3K27me3 gains associated with global 
reprogramming of H3K27me3 levels, irrespective of mRNA expression changes, are 
shown (white bars). Significant p values (*) are shown based on observed vs 
expected levels of H3K27me3 gains or losses at promoters (Yates Chi-squared or 
Fischer Exact tests). g. Schematic representation of H3K27me3 reprogramming in 
CML leading to increased mechanistic coupling of H3K27me3 levels and mRNA 
expression - consistent with an altered dependency for EZH2 in CML (upward green 
arrow). HSCs require EZH1(14) but not EZH2(15) (downward green arrow). 
 
Figure 2. CML cells are sensitive to chemical and genetic inhibition of EZH2. a. 
Schematic for EZH2i treatment in primary CML and normal CD34+ cells. n = 3 
bioreplicates in all instances described below. b. Representative western analysis of 
H3K27me3 and H3K27me1 levels in CML and normal CD34+ cells treated for 6 days 
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with increasing concentrations of EZH2i as indicated. L = laemmli buffer; total cellular 
protein. A = acid extraction; enriched for histones. Levels of bulk histone H3 were 
used as loading controls. c. Viability of CML and normal CD34+ cells treated with 
EZH2i for 6 days. Mean total viable cell counts (top); mean viable undivided 
(CTVmax) CD34+ cells (bottom). d. Levels of apoptosis (Annexin V-positive cells) in 
CML and normal CD34+ cells treated with EZH2i. Mean total apoptosis (top) and 
mean apoptosis in undivided (CTVmax) CD34+ cells (bottom). e. Colonogenic (CFC) 
potential of CML and normal CD34+ cells treated with EZH2i. Mean total CFC 
outputs (top) and  GEMM outputs (bottom) from CD34+ cells; total CFC outputs from 
LSCs (CD34+CD38-) (bottom). f. Colonogenic potential of CML and normal CD34+ 
cells from LTC-IC after 3 days or 6 days treatment with EZH2i. % of cells Ph+ (i.e., 
BCR-ABL+) in NDC (day 6) is shown by the arrowhead (red). g. Effect of EZH2 
shRNA knockdown in CML34+ cells. Cell counts (left), CFC output (middle) and 
apoptosis (Annexin V-positive cells) (right) for CML CD34+ cells transduced with 
EZH2 or control shRNA for 3 days. Two different EZH2 shRNAs were used to derive 
data. h. Scatterplot depicting global mRNA expression changes (Z-scores) for 975 
and 1473 genes in CML and normal CD34+ cells respectively as a consequence of 
EZH2i treatment (and where both mRNA and H3K27me3 status is known) (E-MTAB-
2893; E-MTAB-3552). H3K27me3 targets (> +/- 1 SD from the mean) are highlighted 
(red). Significant p values (*; one sample t-tests in c → g) are shown in the key 
below panel g. EZH2i is GSK343 for data shown in b → f and in h. i. Venn diagrams 
depict the degree of overlap between genes showing mRNA changes due to EZH2i 
treatment in CML and normal CD34+ cells; all genes (top), H3K27me3 target genes 
(bottom). % of overlap with respect to totals for CML CD34+ cells (left). 
 
Figure 3. Both TKI and EZH2i up-regulate H3K27me3 targets and combined 
treatment potentiates loss of LSCs. a. Summary of global mean mRNA 
expression changes found in LSCs after treatment with TKI for 7 days in vitro based 
on Affymetrix analysis (E-MTAB-2594). Percentages of genes up- or down-regulated 
are shown for H3K27me3 targets and other genes for each TKI treatment (n = 6 
bioreplicates in all cases). Total number of mRNAs affected shown along the bottom. 
b. Representative western analysis (L = laemmli buffer) of H3K27me3 and 
H3K27me1 levels in CML CD34+ treated with DAS with and without increasing 
concentrations of EZH2i (GSK343). c. Viability of CML CD34+ cells treated with 
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EZH2i and DAS for 6 days. Mean total viable cell counts (left); mean viable 
undivided (CTVmax) CD34+ cells (right). d. Levels of apoptosis (Annexin V-positive 
cells) in CML CD34+ cells treated with EZH2i and DAS for 6 days. Mean total 
apoptosis (left) and mean apoptosis in undivided (CTVmax) CD34+ cells (right). e. 
Colonogenic (CFC) potential of CML cells treated with EZH2i and DAS for 6 days. 
Mean total CFC outputs (left) and GEMM outputs (middle) from CML CD34+ cells 
and total CFC outputs from LSCs (CD34+CD38-) (right). f. Colonogenic potential of 
CML CD34+ cells from LTC-IC following 3 or 6 day treatment with EZH2i and DAS 
(same samples as shown in Fig. 3e). Expected levels (green dotted line) are based 
on efficacy of EZH2i alone on CD34+ cells (from Fig. 3f). g. Cell counts (left) and 
CFC output (right) for CML CD34+ cells transduced with EZH2 or control shRNA for 
4 days in the presence of DAS. Two different EZH2 shRNAs were used to derive 
data. Results in c → g are shown as a percentage change from treatment with DAS 
(150 nM) only, unless indicated. n = 3 bioreplicates in c,d,e,f; n = 4 bioreplicates in g. 
h. Schematic showing the experimental design for EZH2i and TKI treatment of NSG 
mice engrafted with CML CD34+ samples. i. Representative FACs scatter plots 
showing the proportions (%) of human CML CD45+ cells staining positive for CD34+ 
(hCD34+) in bone marrow from NSG xenografts following in vivo treatment with 
EZH2i (EPZ-6438) or TKI (nilotinib; NIL) alone and in combination for 25 days. SSC 
= side scatter. j. Left side, mean absolute number (top) and mean % (bottom) of Ph+ 
hCD45+ cells from bone marrow of NSG xenografts treated with vehicle (NDC), 
EZH2i, NIL (nilotinib) and EZH2i + NIL (25 day treatment; n = 2 CML CD34+ 
samples; n = 8 mice per arm). Right side, mean absolute number (top) and mean % 
(bottom) Ph+ hCD45+CD34+ cells from the same experiments. k. Mean absolute 
number (top) and mean % (bottom) of Ph+ hCD45+CD34+CD38- cells from bone 
marrow of NSG xenografts treated as above (n = 1 CML CD34+ sample; n = 3-4 
mice per arm). In j, k, % Ph+ cells are expressed as a % of hCD45+ in NDC. 
Significant p values (*; one sample t-tests in c → g; Student t-tests in bar diagrams of 
j, k) are as shown in the key next to panel k. 
 
Figure 4: Molecular analysis of the effects of EZH2i and TKI on apoptotic- 
pathways in CML CD34+ cells. a. Main panel, heat maps showing mean fold 
changes in the mRNA expression (Fluidigm) of a number of apoptotic pathway 
genes following treatment of CML CD34+ samples with EZH2i (1000 nM) or DAS 
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(150 nM) alone or in combination (n =4 bioreplicates assayed in triplicate); mean 
changes in mRNA expression of specific p53 pathway genes and BCL6 are shown 
(right). b. Bar diagrams showing comparisons of predicted (from individual 
treatments using an additive model; grey) and actual changes in mean mRNA 
expression levels of H3K27me3 (blue; left) and other targets (pink; right) following 
treatment with both EZH2i and DAS in each bioreplicate CML sample (n = 4) shown 
in a. Error bars are SEMs in all instances. Significant p values (*; one sample t-tests 
in a, Student t-tests in bar diagrams of b) are as shown in the key next to panel b. c. 
Representative western analysis (laemmli buffer) of p53 levels in two CML CD34+ 
samples before and after EZH2i +/- DAS treatment. d. Schematic of a putative 
interactome map between EZH2/H3K27me3 (blue), BCL6 (red) and p53 (purple) 
targets which mediate cell cycle arrest and apoptosis in CML CD34+ cells. BCL6 
targets were obtained from previously published data(22). BCL6 is self-regulatory as 
shown. Cell cycle inhibitors and activators are shown in orange and green 
respectively.  
 
 




